The Trump administration on Sunday granted emergency authorization of convalescent plasma to treat hospitalized Covid-19 patients, despite concerns from some of the nation’s top health officials that data from clinical trials is too weak to support widespread application of the treatment at this time.

The Food and Drug Administration, in a letter Sunday, said it was granting emergency authorization because it is reasonable to believe that convalescent plasma may be effective in treating Covid-19 patients, and the known and potential benefits outweigh the known and potential risks of such products.

“Today’s action will dramatically expand access to this treatment,” President Trump said at a White House press conference on Sunday …continued .
[Source: CNBC News]